First Light Asset Management LLC Sells 196,449 Shares of MiMedx Group, Inc $MDXG

First Light Asset Management LLC trimmed its holdings in MiMedx Group, Inc (NASDAQ:MDXG) by 6.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,842,892 shares of the company’s stock after selling 196,449 shares during the period. MiMedx Group comprises about 1.0% of First Light Asset Management LLC’s investment portfolio, making the stock its 29th largest holding. First Light Asset Management LLC owned about 1.91% of MiMedx Group worth $11,229,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of MDXG. SkyView Investment Advisors LLC raised its position in shares of MiMedx Group by 3.6% during the second quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock worth $523,000 after purchasing an additional 3,032 shares during the period. Rafferty Asset Management LLC grew its position in shares of MiMedx Group by 4.6% in the 4th quarter. Rafferty Asset Management LLC now owns 69,304 shares of the company’s stock valued at $469,000 after purchasing an additional 3,064 shares during the period. Aviva PLC grew its position in shares of MiMedx Group by 4.7% in the 4th quarter. Aviva PLC now owns 71,234 shares of the company’s stock valued at $482,000 after purchasing an additional 3,211 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in MiMedx Group by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock worth $559,000 after purchasing an additional 4,049 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in MiMedx Group by 42.6% during the 1st quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock worth $109,000 after purchasing an additional 4,296 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Price Performance

Shares of MiMedx Group stock opened at $4.20 on Monday. The business’s 50 day simple moving average is $3.86 and its 200 day simple moving average is $4.30. MiMedx Group, Inc has a 52-week low of $3.03 and a 52-week high of $7.99. The firm has a market cap of $625.59 million, a PE ratio of 21.00 and a beta of 1.45. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.81 and a current ratio of 5.39.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, April 29th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. MiMedx Group had a net margin of 7.88% and a return on equity of 21.03%. The company had revenue of $58.99 million during the quarter, compared to analysts’ expectations of $65.80 million. On average, analysts predict that MiMedx Group, Inc will post -0.09 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Citizens Jmp cut their price target on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a research note on Thursday, April 30th. Wall Street Zen downgraded shares of MiMedx Group from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Weiss Ratings lowered shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 18th. Finally, Craig Hallum cut their price objective on shares of MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, MiMedx Group presently has a consensus rating of “Moderate Buy” and an average target price of $8.50.

MiMedx Group Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.